Reine Allan 4

What Happened Reine Allan, CEO of Prime Medicine, was granted a derivative equity award covering 1,300,000 shares on February 26, 2026. The award is reported at $0.00 per share (no cash paid at grant) and is recorded as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (appears filed the next day).
• Award type: Derivative equity award (reported as "A"); reported acquisition of 1,300,000 shares at $0.00.
• Vesting: Footnote F1 — 1/48th of the shares underlying this option vest in substantially equal monthly installments beginning on Feb 26, 2026 (about 27,083 shares per month), subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Not marked as late; filing date is one day after the transaction.

Context This transaction is a compensation-related grant to the CEO, not an open-market buy or sale. As a derivative award with multi-year monthly vesting, the grant vests over four years and does not indicate an immediate sale or purchase by the insider. Grants are common for executive pay and retention; they are informative about compensation but do not by themselves signal a buy or sell decision.